Purple Stock Based Compensation To Revenue from 2010 to 2025
| PPBT Stock | USD 4.51 0.08 1.74% |
Stock Based Compensation To Revenue | First Reported 2010-12-31 | Previous Quarter 11.01 | Current Value 8.22 | Quarterly Volatility 9.00182929 |
Check Purple Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Purple Biotech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 240.3 K, Interest Expense of 2.6 M or Selling General Administrative of 4.6 M, as well as many indicators such as Price To Sales Ratio of 84.89, Dividend Yield of 0.088 or PTB Ratio of 0.49. Purple financial statements analysis is a perfect complement when working with Purple Biotech Valuation or Volatility modules.
Purple | Stock Based Compensation To Revenue |
Latest Purple Biotech's Stock Based Compensation To Revenue Growth Pattern
Below is the plot of the Stock Based Compensation To Revenue of Purple Biotech over the last few years. It is a metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards. Purple Biotech's Stock Based Compensation To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Purple Biotech's overall financial position and show how it may be relating to other accounts over time.
| Stock Based Compensation To Revenue | 10 Years Trend |
|
Stock Based Compensation To Revenue |
| Timeline |
Purple Stock Based Compensation To Revenue Regression Statistics
| Arithmetic Mean | 14.83 | |
| Geometric Mean | 10.32 | |
| Coefficient Of Variation | 60.70 | |
| Mean Deviation | 8.25 | |
| Median | 23.08 | |
| Standard Deviation | 9.00 | |
| Sample Variance | 81.03 | |
| Range | 22.307 | |
| R-Value | (0.73) | |
| Mean Square Error | 40.97 | |
| R-Squared | 0.53 | |
| Significance | 0 | |
| Slope | (1.37) | |
| Total Sum of Squares | 1,215 |
Purple Stock Based Compensation To Revenue History
About Purple Biotech Financial Statements
Purple Biotech shareholders use historical fundamental indicators, such as Stock Based Compensation To Revenue, to determine how well the company is positioned to perform in the future. Although Purple Biotech investors may analyze each financial statement separately, they are all interrelated. The changes in Purple Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses on on Purple Biotech's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Stock Based Compensation To Revenue | 11.01 | 8.22 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Purple Stock Analysis
When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.